Meet the Nextnet team

Miki is a trained executive and entrepreneur who started his career as a programmer and built expertise in company growth and VC investment. He led executive roles in notorious Silicon Valley tech companies such as Netscape and was a Board Member for several technology companies and organizations, including Kakaku.com where he was also the CTO/COO, Digital Garage, UCSF Health Hub, McGill Japan Advisory Board among others. He was formerly CEO of Open Network Lab, an incubator for global-minded entrepreneurs in Japan, and CEO of Neo, a San Francisco based lean startup consulting company. Later on, he joined DeNA San Francisco where he led its early-stage investment. Miki earned his BS from Rochester Institute of Technology and MBA from McGill University.

Dr. Manish Singhal is an entrepreneur with more than twenty years of healthcare and biopharmaceutical industry experience. He is a founding member of MedCI, a consulting firm facilitating international business and corporate development transactions, and Arbormed, a Series A biotech startup developing therapeutics for rare diseases. He received his MD degree from the University of Texas and his MBA degree from the University of Michigan.

Gerald Dennig was Goldman Sachs CIO and former Head of Portfolio Management UBS Asia. He built complex enterprise solutions for Chase, UBS, and Goldman over a span of two decades. He also has worked extensively in private wealth for UHNW families. Gerald graduated from Princeton University with a Bachelor’s degree in History and Development Economics.

Dr. Cassian Yee is a pioneer in the field of adoptive cellular therapy, and over the last two decades has developed specialized forms of antigen-specific T-cell therapies for the treatment of patients with cancer. As a physician-scientist, his research converges multi-disciplinary approaches in bioengineering, metabolism, epigenetics, and molecular immunology into enabling technologies that render adoptive cell therapy more effective and accessible as a treatment modality for patients. Cassian is currently the Director of the Solid Tumor Cell Therapy Program at MD Anderson Cancer Center and previously held positions at the University of Washington and the Fred Hutchinson Cancer Research Center.

LinkedIn

Dr. Daniel B. Goodman is a synthetic biologist who specializes in the high-throughput computational design and engineering of bacterial and mammalian genomes. He completed his PhD at the Harvard-MIT HST program in the lab of Prof. George Church. His work has been featured in journals including Science, Cell, PNAS, Nature Biotechnology, and Genome Research. Dan is currently Jane Coffin Childs Postdoctoral Fellow at the University of California, San Francisco, where he is developing new multiplexed genome editing and measurement technologies to engineer primary human immune cells to treat disease.

Dr. Michael Fenn is currently the Director of External Innovation at Dewpoint Therapeutics. Previously, he led the Healthcare & Life Sciences group at Harvard Innovation Labs and Co-led the planning of Life Lab Longwood at Harvard Medical School. He received his PhD in Biomedical Engineering, MS in Materials Science and Engineering, and BS in Biochemistry, all from the University of Florida. Mike has co-founded multiple startups that led to $35M+ in venture funding, FDA clearance, formation of strategic partnerships, scale-up to GMP manufacturing, creation and licensing of intellectual property, as well as a successful exit.